What is the recommended neoadjuvant chemotherapy regimen for breast cancer, including anthracycline‑taxane backbone, HER2‑targeted therapy for HER2‑positive disease, carboplatin addition for triple‑negative disease, and alternatives for patients with contraindications to anthracyclines or taxanes?

Neoadjuvant Chemotherapy for Breast Cancer

For HER2-positive stage II-III breast cancer, use neoadjuvant chemotherapy with dual HER2 blockade (trastuzumab + pertuzumab) combined with either anthracycline-taxane or taxane-carboplatin backbone; for triple-negative breast cancer stage II-III, use pembrolizumab + carboplatin + paclitaxel followed by pembrolizumab + cyclophosphamide + doxorubicin/epirubicin as the preferred regimen. 1, 2

HER2-Positive Breast Cancer

Standard Regimen (Stage II-III)

• Dual HER2 blockade with trastuzumab + pertuzumab is mandatory for neoadjuvant therapy, as it achieves significantly higher pathologic complete response (pCR) rates compared to trastuzumab alone 1
• Continue anti-HER2 therapy for 12 months total, covering both neoadjuvant and adjuvant phases 1

Chemotherapy Backbone Options

You have two evidence-based choices 1:

1. Anthracycline-taxane sequence (traditional approach)

   • Dose-dense AC (doxorubicin/cyclophosphamide) followed by paclitaxel every 2 weeks, OR
   • Dose-dense AC followed by weekly paclitaxel 2

2. Taxane-carboplatin regimen (anthracycline-free alternative)

   • Particularly useful when anthracyclines are contraindicated (cardiac concerns, prior anthracycline exposure)
   • Docetaxel/carboplatin with dual HER2 blockade shows comparable efficacy 1, 3
   • Important caveat: For node-positive disease, anthracycline-containing regimens may still be more effective 2

Anthracycline-Free Option for Select Patients

• Docetaxel/carboplatin/pembrolizumab is listed as "useful in certain circumstances" 2
• Best suited for early-stage TNBC patients without axillary lymph node metastases who cannot receive anthracyclines
• Should NOT routinely substitute for standard regimens in node-positive disease 2

Post-Neoadjuvant Management

• If pCR achieved: Complete 12 months of trastuzumab + pertuzumab 1
• If residual disease (non-pCR): Switch to T-DM1 for up to 14 cycles adjuvantly 1
• Perform regular cardiac assessments before, during, and after therapy 1

Triple-Negative Breast Cancer (TNBC)

Preferred Regimen (Stage II-III) - Category 1

KEYNOTE-522 regimen 2:

1. Pembrolizumab + carboplatin + paclitaxel (neoadjuvant phase)
2. Followed by pembrolizumab + cyclophosphamide + doxorubicin or epirubicin (neoadjuvant phase)
3. Followed by adjuvant pembrolizumab

This achieves pCR rates of approximately 65% 2

Alternative for Stage I TNBC

For lower-risk disease, consider 2:

• Dose-dense AC followed by paclitaxel every 2 weeks, OR
• Dose-dense AC followed by weekly paclitaxel, OR
• TC (docetaxel + cyclophosphamide)

Carboplatin Addition

Carboplatin significantly improves pCR rates in TNBC when added to taxane-anthracycline regimens 4, 5. The evidence strongly supports platinum incorporation, though it increases risk of:

• Febrile neutropenia
• Grade 3-4 thrombocytopenia 4

Post-Neoadjuvant Management for TNBC

• If residual disease after taxane/alkylator/anthracycline-based therapy: Add adjuvant capecitabine 2
• If germline BRCA1/2 mutation: Add adjuvant olaparib 1, 2

Alternatives for Anthracycline Contraindications

When anthracyclines cannot be used (cardiac dysfunction, prior anthracycline exposure):

For HER2-Positive Disease:

• Taxane-carboplatin + trastuzumab + pertuzumab is the evidence-based alternative 1
• Nab-paclitaxel (100 mg/m²) + carboplatin (AUC 2) on days 1,8,15 every 4 weeks for 4 cycles shows 64% pCR in HER2-positive disease 3

For TNBC:

• Docetaxel/carboplatin/pembrolizumab (6 cycles) achieves 58% pCR overall, 65% in node-negative patients 2
• Critical limitation: Only 45% pCR in node-positive patients, inferior to KEYNOTE-522 regimen 2
• Reserve this for patients who absolutely cannot receive anthracyclines AND have node-negative disease

Alternatives for Taxane Contraindications

The evidence base is weaker here, but options include:

• Anthracycline-based regimens with carboplatin (though taxanes are generally better tolerated than anthracyclines)
• Consider alternative taxanes first (docetaxel, paclitaxel, nab-paclitaxel can be substituted for each other due to hypersensitivity) 2

Key Clinical Pitfalls

1. Do not omit dual HER2 blockade in HER2-positive stage II-III disease—pertuzumab addition is non-negotiable 1

2. Do not use anthracycline-free regimens routinely in node-positive TNBC—they are inferior to KEYNOTE-522 2

3. Monitor renal function when using carboplatin—dose adjust for creatinine clearance <60 mL/min using Calvert formula 6

4. Cardiac monitoring is essential with HER2-directed therapy, especially if using anthracyclines 1

5. Do not combine olaparib and abemaciclib due to overlapping toxicities; if both indicated, give olaparib first 1